Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
Background and objective: The role of genetic variants in response to systemic therapy in muscle-invasive bladder cancer (MIBC) is still elusive. We assessed variations in genes involved in DNA damage repair (DDR) before and after cisplatin-based neoadjuvant chemotherapy (NAC) and correlation of alt...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | European Urology Open Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168324014137 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841533232434118656 |
|---|---|
| author | Ursula Lemberger Büsra Ernhofer Sigurd Krieger Andreas Bruchbacher André Oszwald Ekaterina Laukhtina Andrea Haitl Melanie R. Hassler Bernhard Englinger Eva Compérat Shahrokh F. Shariat |
| author_facet | Ursula Lemberger Büsra Ernhofer Sigurd Krieger Andreas Bruchbacher André Oszwald Ekaterina Laukhtina Andrea Haitl Melanie R. Hassler Bernhard Englinger Eva Compérat Shahrokh F. Shariat |
| author_sort | Ursula Lemberger |
| collection | DOAJ |
| description | Background and objective: The role of genetic variants in response to systemic therapy in muscle-invasive bladder cancer (MIBC) is still elusive. We assessed variations in genes involved in DNA damage repair (DDR) before and after cisplatin-based neoadjuvant chemotherapy (NAC) and correlation of alteration patterns with DNA damage and response to therapy. Methods: Matched tissue from 46 patients with MIBC was investigated via Ion Torrent–based next-generation sequencing using a self-designed panel of 30 DDR genes. Phosphorylation of γ-histone 2A.X (H2AX) was analyzed via immunohistochemistry to evaluate DNA damage. Genetic variants were analyzed along with clinical data and quantitative phospho-H2AX data using the Kaplan-Meier method, Cox regression analysis, and factor analysis of mixed data. Key findings and limitations: Twenty-five patients (54%) had a response (<pT2 pN0 cM0) to NAC. Responders had more somatic DDR gene variants in preNAC (53 vs 11; p < 0.001) and postNAC (51 vs 9; p = 0.038) tumor tissue in comparison to nonresponders, as well as significantly greater phosphorylation of H2AX after NAC. ERCC2 was significantly co-mutated with REV3L among responders. Owing to the small cohort, no specific mutation was significantly positively associated with therapy response. However, accumulation of CDK12, NBN, MSH3, MLH1, ATR, BRCA1, BRCA2, REVL3L, and SLX4 variants was observed for responders. Conclusions and clinical implications: Patients with MIBC who responded to cisplatin-based NAC had more somatic DDR gene variants than nonresponders. Moreover, responders exhibited significantly greater DNA damage after NAC. Patient summary: Patients with muscle-invasive bladder cancer who have mutations in genes that are involved in repair of DNA damage are more likely to respond to cisplatin-based chemotherapy. Testing to identify these gene mutations could help in selecting the patients who are most likely to benefit from this treatment. |
| format | Article |
| id | doaj-art-543b7ef7c4374be7977e14ee8e6b39f8 |
| institution | Kabale University |
| issn | 2666-1683 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | European Urology Open Science |
| spelling | doaj-art-543b7ef7c4374be7977e14ee8e6b39f82025-01-17T04:52:20ZengElsevierEuropean Urology Open Science2666-16832025-01-01713848Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerUrsula Lemberger0Büsra Ernhofer1Sigurd Krieger2Andreas Bruchbacher3André Oszwald4Ekaterina Laukhtina5Andrea Haitl6Melanie R. Hassler7Bernhard Englinger8Eva Compérat9Shahrokh F. Shariat10Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Corresponding author. Department of Urology, Medical University of Vienna, Vienna, Austria.Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, AustriaClinical Institute of Pathology, Medical University of Vienna, Vienna, AustriaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, AustriaClinical Institute of Pathology, Medical University of Vienna, Vienna, AustriaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, AustriaClinical Institute of Pathology, Medical University of Vienna, Vienna, AustriaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, AustriaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Center for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, AustriaClinical Institute of Pathology, Medical University of Vienna, Vienna, AustriaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, JordanBackground and objective: The role of genetic variants in response to systemic therapy in muscle-invasive bladder cancer (MIBC) is still elusive. We assessed variations in genes involved in DNA damage repair (DDR) before and after cisplatin-based neoadjuvant chemotherapy (NAC) and correlation of alteration patterns with DNA damage and response to therapy. Methods: Matched tissue from 46 patients with MIBC was investigated via Ion Torrent–based next-generation sequencing using a self-designed panel of 30 DDR genes. Phosphorylation of γ-histone 2A.X (H2AX) was analyzed via immunohistochemistry to evaluate DNA damage. Genetic variants were analyzed along with clinical data and quantitative phospho-H2AX data using the Kaplan-Meier method, Cox regression analysis, and factor analysis of mixed data. Key findings and limitations: Twenty-five patients (54%) had a response (<pT2 pN0 cM0) to NAC. Responders had more somatic DDR gene variants in preNAC (53 vs 11; p < 0.001) and postNAC (51 vs 9; p = 0.038) tumor tissue in comparison to nonresponders, as well as significantly greater phosphorylation of H2AX after NAC. ERCC2 was significantly co-mutated with REV3L among responders. Owing to the small cohort, no specific mutation was significantly positively associated with therapy response. However, accumulation of CDK12, NBN, MSH3, MLH1, ATR, BRCA1, BRCA2, REVL3L, and SLX4 variants was observed for responders. Conclusions and clinical implications: Patients with MIBC who responded to cisplatin-based NAC had more somatic DDR gene variants than nonresponders. Moreover, responders exhibited significantly greater DNA damage after NAC. Patient summary: Patients with muscle-invasive bladder cancer who have mutations in genes that are involved in repair of DNA damage are more likely to respond to cisplatin-based chemotherapy. Testing to identify these gene mutations could help in selecting the patients who are most likely to benefit from this treatment.http://www.sciencedirect.com/science/article/pii/S2666168324014137Cisplatin-based neoadjuvant chemotherapyDNA repair genesMutationMuscle-invasive bladder cancerNext-generation sequencing |
| spellingShingle | Ursula Lemberger Büsra Ernhofer Sigurd Krieger Andreas Bruchbacher André Oszwald Ekaterina Laukhtina Andrea Haitl Melanie R. Hassler Bernhard Englinger Eva Compérat Shahrokh F. Shariat Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer European Urology Open Science Cisplatin-based neoadjuvant chemotherapy DNA repair genes Mutation Muscle-invasive bladder cancer Next-generation sequencing |
| title | Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer |
| title_full | Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer |
| title_fullStr | Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer |
| title_full_unstemmed | Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer |
| title_short | Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer |
| title_sort | alterations in dna damage repair genes before and after neoadjuvant cisplatin based chemotherapy in muscle invasive bladder cancer |
| topic | Cisplatin-based neoadjuvant chemotherapy DNA repair genes Mutation Muscle-invasive bladder cancer Next-generation sequencing |
| url | http://www.sciencedirect.com/science/article/pii/S2666168324014137 |
| work_keys_str_mv | AT ursulalemberger alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer AT busraernhofer alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer AT sigurdkrieger alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer AT andreasbruchbacher alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer AT andreoszwald alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer AT ekaterinalaukhtina alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer AT andreahaitl alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer AT melanierhassler alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer AT bernhardenglinger alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer AT evacomperat alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer AT shahrokhfshariat alterationsindnadamagerepairgenesbeforeandafterneoadjuvantcisplatinbasedchemotherapyinmuscleinvasivebladdercancer |